| Gene symbol | CD40LG | Synonyms | CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD40 ligand | ||||
| Gene symbol | CD70 | Synonyms | CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.3 | dbXrefs | |
| Description | CD70 molecule | ||||
| Gene symbol | PMEL | Synonyms | D12S53E, HMB-45, HMB45, ME20, ME20-M, ME20M, P1, P100, PMEL17, SI, SIL, SILV, gp100 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.2 | dbXrefs | |
| Description | premelanosome protein | ||||
| Gene symbol | MAGEC2 | Synonyms | CT10, HCA587, MAGEE1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq27.2 | dbXrefs | |
| Description | MAGE family member C2 | ||||
| Gene symbol | PRAME | Synonyms | CT130, MAPE, OIP-4, OIP4 | Type of gene | protein-coding |
| Chromosome | 22 | Map location | 22q11.22 | dbXrefs | |
| Description | PRAME nuclear receptor transcriptional regulator | ||||
| Gene symbol | TLR4 | Synonyms | ARMD10, CD284, TLR-4, TOLL | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | toll like receptor 4 | ||||
| Gene symbol | TYR | Synonyms | ATN, CMM8, OCA1, OCA1A, OCAIA, SHEP3 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q14.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | tyrosinase | ||||
| GTO ID | GTC1851 |
| Trial ID | NCT03394937 |
| Disease | Melanoma |
| Altered gene | CD40LG|TLR4|CD70|TYR|gp100|MAGE-C2|PRAME |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | ECI-006 |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment |
| Year | 2017 |
| Country | Belgium|Spain |
| Company sponsor | eTheRNA immunotherapies |
| Other ID(s) | E011-MEL |
| Vector information | |||
|
|||
| Cohort1: ECI-006_dose level 1_up to 5 doses | |||||||
|
|||||||
| Cohort2: ECI-006_dose level 2_up to 5 doses | |||||||
|
|||||||
| Cohort3: ECI-006_dose level 2_up to 9 doses | |||||||
|
|||||||
| Cohort4: ECI-006_dose level 3_up to 9 doses | |||||||
|
|||||||